Amprion launches new spinal fluid test to help differentiate MSA from Parkinson’s
Amprion has launched SAAmplify-αSYN Plus, a next-generation cerebrospinal fluid test designed to detect alpha-synuclein aggregates with an MSA-like amplification profile, and made it available on 15 September 2026. The test features an extended run time while maintaining the same reporting turnaroun
<p>Amprion has launched SAAmplify-αSYN Plus, a next-generation cerebrospinal fluid test designed to detect alpha-synuclein aggregates with an MSA-like amplification profile, and made it available on 15 September 2026. The test features an extended run time while maintaining the same reporting turnaroun</p>